Carr S, Smith C, Wernberg J. Epidemiology and risk factors of melanoma. Surg Clin. 2020;100(1):1–12.
Google Scholar
Davis LE, Shalin SC, Tackett AJ. Current state of melanoma diagnosis and treatment. Cancer Biol Ther. 2019;20(11):1366–79.
Article
CAS
PubMed
PubMed Central
Google Scholar
Domingues B, et al. Melanoma treatment in review. ImmunoTargets Ther. 2018;7:35.
Article
CAS
PubMed
PubMed Central
Google Scholar
Seth R, et al. Systemic therapy for melanoma: ASCO guideline. J Clin Oncol. 2020;38(33):3947–70.
Article
CAS
PubMed
Google Scholar
Yu W-L, Hua Z-C. Chimeric antigen receptor T-cell (CAR T) therapy for hematologic and solid malignancies: efficacy and safety—a systematic review with meta-analysis. Cancers. 2019;11(1):47.
Article
CAS
PubMed
PubMed Central
Google Scholar
Roex G, et al. Chimeric antigen receptor-T-cell therapy for B-cell hematological malignancies: an update of the pivotal clinical trial data. Pharmaceutics. 2020;12(2):194.
Article
CAS
PubMed
PubMed Central
Google Scholar
Stoiber S, et al. Limitations in the design of chimeric antigen receptors for cancer therapy. Cells. 2019;8(5):472.
Article
CAS
PubMed
PubMed Central
Google Scholar
Beauvais D, et al. Clinical data, limitations and perspectives on chimeric antigen receptor T-cell therapy in multiple myeloma. Curr Opin Oncol. 2020;32(5):418–26.
Article
CAS
PubMed
Google Scholar
Yilmaz A, et al. Chimeric antigen receptor-engineered natural killer cells for cancer immunotherapy. J Hematol Oncol. 2020;13(1):1–22.
Article
Google Scholar
Pfefferle A, Huntington ND. You have got a fast CAR: chimeric antigen receptor NK cells in cancer therapy. Cancers. 2020;12(3):706.
Article
CAS
PubMed
PubMed Central
Google Scholar
Li Y, et al. Human iPSC-derived natural killer cells engineered with chimeric antigen receptors enhance anti-tumor activity. Cell Stem Cell. 2018;23(2):181–92 e5.
Article
CAS
PubMed
PubMed Central
Google Scholar
Gong Y, et al. Chimeric antigen receptor natural killer (CAR-NK) cell design and engineering for cancer therapy. J Hematol Oncol. 2021;14(1):1–35.
Article
CAS
Google Scholar
Wang L, et al. Chimeric antigen receptor (CAR)-modified NK cells against cancer: opportunities and challenges. Int Immunopharmacol. 2019;74:105695.
Article
CAS
PubMed
Google Scholar
Yu M, et al. Development of GPC3-specific chimeric antigen receptor-engineered natural killer cells for the treatment of hepatocellular carcinoma. Mol Ther. 2018;26(2):366–78.
Article
CAS
PubMed
Google Scholar
Schubert ML, et al. Chimeric antigen receptor transduced T cells: tuning up for the next generation. Int J Cancer. 2018;142(9):1738–47.
Article
CAS
PubMed
Google Scholar
Azoulay E, et al. Critical care management of chimeric antigen receptor T cell–related toxicity. Be aware and prepared. Am J Respir Crit Care Med. 2019;200(1):20–3.
Article
PubMed
Google Scholar
Guo Y, et al. Mutant B2M-HLA-E and B2M-HLA-G fusion proteins protects universal chimeric antigen receptor-modified T cells from allogeneic NK cell-mediated lysis. Eur J Immunol. 2021;51(10):2513–21.
Article
CAS
PubMed
PubMed Central
Google Scholar
Hosseini M, et al. Preclinical studies of chimeric antigen receptor-modified natural killer cells in cancer immunotherapy: a review. Expert Opin Biol Ther. 2021;22:1–18.
Morgan MA, et al. Improved activity against acute myeloid leukemia with chimeric antigen receptor (CAR)-NK-92 cells designed to target CD123. Viruses. 2021;13(7):1365.
Article
CAS
PubMed
PubMed Central
Google Scholar
Parlar A, et al. Engineering antigen-specific NK cell lines against the melanoma-associated antigen tyrosinase via TCR gene transfer. Eur J Immunol. 2019;49(8):1278–90.
CAS
PubMed
Google Scholar
Tarazona R, Duran E, Solana R. Natural killer cell recognition of melanoma: new clues for a more effective immunotherapy. Front Immunol. 2016;6:649.
Article
PubMed
PubMed Central
Google Scholar
Lam BQ, et al. Accumulation and anti-tumor effect of chimeric antigen receptor (CAR) NK cells in metastasis uveal melanoma: AACR; 2019.
Google Scholar
Soltantoyeh T, et al. Chimeric antigen receptor (CAR) T cell therapy for metastatic melanoma: challenges and road ahead. Cells. 2021;10(6):1450.
Article
CAS
PubMed
PubMed Central
Google Scholar
van Vliet AA, et al. Adoptive NK cell therapy: a promising treatment prospect for metastatic melanoma. Cancers. 2021;13(18):4722.
Article
PubMed
PubMed Central
Google Scholar
Braun M, et al. The CD6 scavenger receptor is differentially expressed on a CD56dim natural killer cell subpopulation and contributes to natural killer-derived cytokine and chemokine secretion. J Innate Immunity. 2011;3(4):420–34.
Article
CAS
Google Scholar
Bald T, et al. The NK cell–cancer cycle: advances and new challenges in NK cell–based immunotherapies. Nat Immunol. 2020;21(8):835–47.
Article
CAS
PubMed
PubMed Central
Google Scholar
Shimasaki N, Jain A, Campana D. NK cells for cancer immunotherapy. Nat Rev Drug Discov. 2020;19(3):200–18.
Article
CAS
PubMed
Google Scholar
Lee H, et al. Targeting NK cells to enhance melanoma response to immunotherapies. Cancers. 2021;13(6):1363.
Article
CAS
PubMed
PubMed Central
Google Scholar
Sivori S, et al. Human NK cells: surface receptors, inhibitory checkpoints, and translational applications. Cell Mol Immunol. 2019;16(5):430–41.
Article
CAS
PubMed
PubMed Central
Google Scholar
Prager I, Watzl C. Mechanisms of natural killer cell-mediated cellular cytotoxicity. J Leukoc Biol. 2019;105(6):1319–29.
Article
CAS
PubMed
Google Scholar
Xie G, et al. CAR-NK cells: a promising cellular immunotherapy for cancer. EBioMedicine. 2020;59:102975.
Article
CAS
PubMed
PubMed Central
Google Scholar
Zhang H, et al. The role of NK cells and CD39 in the immunological control of tumor metastases. Oncoimmunology. 2019;8(6):e1593809.
Article
PubMed
PubMed Central
Google Scholar
Chiossone L, et al. Natural killer cells and other innate lymphoid cells in cancer. Nat Rev Immunol. 2018;18(11):671–88.
Article
CAS
PubMed
Google Scholar
Rückert M, et al. Immune modulatory effects of radiotherapy as basis for well-reasoned radioimmunotherapies. Strahlenther Onkol. 2018;194(6):509–19.
Article
PubMed
Google Scholar
de Jonge K, et al. Circulating CD56bright NK cells inversely correlate with survival of melanoma patients. Sci Rep. 2019;9(1):1–10.
Article
Google Scholar
Ali TH, et al. Enrichment of CD56dimKIR+ CD57+ highly cytotoxic NK cells in tumour-infiltrated lymph nodes of melanoma patients. Nat Commun. 2014;5(1):1–9.
Article
CAS
Google Scholar
Vujanovic L, et al. CD56dim CD16− natural killer cell profiling in melanoma patients receiving a cancer vaccine and interferon-α. Front Immunol. 2019;10:14.
Article
CAS
PubMed
PubMed Central
Google Scholar
Messaoudene M, et al. Mature cytotoxic CD56bright/CD16+ natural killer cells can infiltrate lymph nodes adjacent to metastatic melanoma. Cancer Res. 2014;74(1):81–92.
Article
CAS
PubMed
Google Scholar
Frazao A, et al. CD16+ NKG2Ahigh Natural Killer Cells Infiltrate Breast Cancer–Draining Lymph Nodes. Cancer Immunol Res. 2019;7(2):208–18.
Article
CAS
PubMed
Google Scholar
Martinovic KMM, et al. Decreased expression of NKG2D, NKp46, DNAM-1 receptors, and intracellular perforin and STAT-1 effector molecules in NK cells and their dim and bright subsets in metastatic melanoma patients. Melanoma Res. 2014;24(4):295–304.
Article
Google Scholar
Stojanovic A, Cerwenka A. Natural killer cells and solid tumors. J Innate Immun. 2011;3(4):355–64.
Article
PubMed
Google Scholar
Melaiu O, et al. Influence of the tumor microenvironment on NK cell function in solid tumors. Front Immunol. 2020:3038.
Ng YY, Tay JC, Wang S. CXCR1 expression to improve anti-cancer efficacy of intravenously injected CAR-NK cells in mice with peritoneal xenografts. Mol Ther Oncolytics. 2020;16:75–85.
Article
CAS
PubMed
Google Scholar
Ang WX, et al. Intraperitoneal immunotherapy with T cells stably and transiently expressing anti-EpCAM CAR in xenograft models of peritoneal carcinomatosis. Oncotarget. 2017;8(8):13545.
Article
PubMed
PubMed Central
Google Scholar
Sottile R, et al. NK-and T-cell subsets in malignant mesothelioma patients: baseline pattern and changes in the context of anti-CTLA-4 therapy. Int J Cancer. 2019;145(8):2238–48.
Article
CAS
PubMed
Google Scholar
Kohlhapp FJ, et al. NK cells and CD8+ T cells cooperate to improve therapeutic responses in melanoma treated with interleukin-2 (IL-2) and CTLA-4 blockade. J Immunother Cancer. 2015;3(1):1–13.
Article
Google Scholar
Crome SQ, et al. Natural killer cells regulate diverse T cell responses. Trends Immunol. 2013;34(7):342–9.
Article
CAS
PubMed
Google Scholar
Morandi F, et al. CD56brightCD16− NK cells produce adenosine through a CD38-mediated pathway and act as regulatory cells inhibiting autologous CD4+ T cell proliferation. J Immunol. 2015;195(3):965–72.
Article
CAS
PubMed
Google Scholar
Cappello S, et al. Protein signatures of NK cell–mediated melanoma killing predict response to immunotherapies. Cancer Res. 2021;81(21):5540–54.
Article
CAS
PubMed
PubMed Central
Google Scholar
Parodi M, et al. Natural killer (NK)/melanoma cell interaction induces NK-mediated release of chemotactic high mobility group Box-1 (HMGB1) capable of amplifying NK cell recruitment. Oncoimmunology. 2015;4(12):e1052353.
Article
PubMed
PubMed Central
Google Scholar
Morgado S, et al. NK cell recognition and killing of melanoma cells is controlled by multiple activating receptor-ligand interactions. J Innate Immun. 2011;3(4):365–73.
Article
CAS
PubMed
Google Scholar
Sayitoglu EC, et al. Boosting natural killer cell-mediated targeting of sarcoma through DNAM-1 and NKG2D. Front Immunol. 2020;11:40.
Article
CAS
PubMed
PubMed Central
Google Scholar
Forsberg EM, et al. HER2 CAR-T cells eradicate uveal melanoma and T-cell therapy–resistant human melanoma in IL2 transgenic NOD/SCID IL2 receptor knockout mice. Cancer Res. 2019;79(5):899–904.
Article
CAS
PubMed
Google Scholar
Kozar I, et al. Many ways to resistance: How melanoma cells evade targeted therapies. Biochimica et Biophysica Acta (BBA)-Reviews on Cancer. 2019;1871(2):313–22.
Article
CAS
PubMed
Google Scholar
Marzagalli M, Ebelt ND, Manuel ER. Unraveling the crosstalk between melanoma and immune cells in the tumor microenvironment. Semin Cancer Biol. 2019;59:236–50. Elsevier.
Huang Z, et al. Targeted delivery of let-7b to reprogramme tumor-associated macrophages and tumor infiltrating dendritic cells for tumor rejection. Biomaterials. 2016;90:72–84.
Article
CAS
PubMed
Google Scholar
Johansson CH, Brage SE. BRAF inhibitors in cancer therapy. Pharmacol Ther. 2014;142(2):176–82.
Article
Google Scholar
Grimaldi AM, et al. MEK inhibitors in the treatment of metastatic melanoma and solid tumors. Am J Clin Dermatol. 2017;18(6):745–54.
Article
PubMed
Google Scholar
Simiczyjew A, et al. The influence of tumor microenvironment on immune escape of melanoma. Int J Mol Sci. 2020;21(21):8359.
Article
CAS
PubMed
PubMed Central
Google Scholar
Cerezo M, et al. Translational control of tumor immune escape via the eIF4F–STAT1–PD-L1 axis in melanoma. Nat Med. 2018;24(12):1877–86.
Article
CAS
PubMed
Google Scholar
Passarelli A, et al. The metabolic milieu in melanoma: role of immune suppression by CD73/adenosine. Tumor Biol. 2019;41(4):1010428319837138.
Article
Google Scholar
Derré L, et al. Expression and release of HLA-E by melanoma cells and melanocytes: potential impact on the response of cytotoxic effector cells. J Immunol. 2006;177(5):3100–7.
Article
PubMed
Google Scholar
Sabrina, R., et al., Autocrine signaling of NRP1 ligand Galectin-1 elicits resistance to BRAF-targeted therapy in melanoma cells. 2020.
Google Scholar
Kim MH, et al. YAP-induced PD-L1 expression drives immune evasion in BRAFi-resistant melanoma. Cancer Immunol Res. 2018;6(3):255–66.
Article
CAS
PubMed
Google Scholar
Chauvin J-M, et al. IL15 stimulation with TIGIT blockade reverses CD155-mediated NK-cell dysfunction in melanoma. Clin Cancer Res. 2020;26(20):5520–33.
Article
CAS
PubMed
PubMed Central
Google Scholar
Kawashima S, et al. TIGIT/CD155 axis mediates resistance to immunotherapy in patients with melanoma with the inflamed tumor microenvironment. J Immunother Cancer. 2021;9(11):e003134.
Ziani L, et al. Hypoxia increases melanoma-associated fibroblasts immunosuppressive potential and inhibitory effect on T cell-mediated cytotoxicity. OncoImmunology. 2021;10(1):1950953.
Article
PubMed
PubMed Central
Google Scholar
Peng Y-P, et al. Elevation of MMP-9 and IDO induced by pancreatic cancer cells mediates natural killer cell dysfunction. BMC Cancer. 2014;14(1):1–12.
Article
Google Scholar
Zhang F, et al. TGF-β induces M2-like macrophage polarization via SNAIL-mediated suppression of a pro-inflammatory phenotype. Oncotarget. 2016;7(32):52294.
Article
PubMed
PubMed Central
Google Scholar
Mandl M, et al. Hypoxia-inducible factor-1β (HIF-1β) is upregulated in a HIF-1α-dependent manner in 518A2 human melanoma cells under hypoxic conditions. Biochem Biophys Res Commun. 2013;434(1):166–72.
Article
CAS
PubMed
Google Scholar
Park E-J, et al. Vanillin suppresses cell motility by inhibiting STAT3-mediated HIF-1α mRNA expression in malignant melanoma cells. Int J Mol Sci. 2017;18(3):532.
Article
PubMed
PubMed Central
Google Scholar
Fang F, et al. Advances in NK cell production. Cell Mol Immunol. 2022:1–22.
Klingemann H, Boissel L, Toneguzzo F. Natural killer cells for immunotherapy–advantages of the NK-92 cell line over blood NK cells. Front Immunol. 2016:91.
Lamas B, et al. Altered functions of natural killer cells in response to L-arginine availability. Cell Immunol. 2012;280(2):182–90.
Article
CAS
PubMed
Google Scholar
Maki G, et al. Factors regulating the cytotoxic activity of the human natural killer cell line, NK-92. J Hematother Stem Cell Res. 2001;10(3):369–83.
Article
CAS
PubMed
Google Scholar
Mallett CL, et al. Migration of iron-labeled KHYG-1 natural killer cells to subcutaneous tumors in nude mice, as detected by magnetic resonance imaging. Cytotherapy. 2012;14(6):743–51.
Article
CAS
PubMed
Google Scholar
Cheng M, et al. Establishment, characterization, and successful adaptive therapy against human tumors of NKG cell, a new human NK cell line. Cell Transplant. 2011;20(11–12):1731–46.
Article
PubMed
Google Scholar
Fujisaki H, et al. Expansion of highly cytotoxic human natural killer cells for cancer cell therapy. Cancer Res. 2009;69(9):4010–7.
Article
CAS
PubMed
PubMed Central
Google Scholar
Glienke W, et al. Advantages and applications of CAR-expressing natural killer cells. Front Pharmacol. 2015;6:21.
Article
PubMed
PubMed Central
Google Scholar
Stikvoort A, et al. CD38-specific chimeric antigen receptor expressing natural killer KHYG-1 cells: a proof of concept for an “off the shelf” therapy for multiple myeloma. HemaSphere. 2021;5(7).
Carlsten M, Childs RW. Genetic manipulation of NK cells for cancer immunotherapy: techniques and clinical implications. Front Immunol. 2015;6:266.
Article
PubMed
PubMed Central
Google Scholar
Kararoudi, M.N., et al. Genetic and epigenetic modification of human primary NK cells for enhanced antitumor activity. Semin Hematol. 2020. Elsevier.
Caudana P, et al. IL2/anti-IL2 complex combined with CTLA-4, but not PD-1, blockade rescues antitumor NK cell function by regulatory T-cell modulation. Cancer Immunol Res. 2019;7(3):443–57.
Article
CAS
PubMed
Google Scholar
Subrahmanyam PB, et al. Distinct predictive biomarker candidates for response to anti-CTLA-4 and anti-PD-1 immunotherapy in melanoma patients. J Immunother Cancer. 2018;6(1):1–14.
Article
Google Scholar
Esen F, Deniz G, Aktas EC. PD-1, CTLA-4, LAG-3, and TIGIT: the roles of immune checkpoint receptors on the regulation of human NK cell phenotype and functions. Immunol Lett. 2021;240:15–23.
Article
CAS
PubMed
Google Scholar
Della Chiesa M, et al. Features of memory-like and PD-1+ human NK cell subsets. Front Immunol. 2016;7:351.
Article
PubMed
PubMed Central
Google Scholar
Mariotti FR, et al. PD-1 in human NK cells: evidence of cytoplasmic mRNA and protein expression. Oncoimmunology. 2019;8(3):1557030.
Article
PubMed
Google Scholar
Sakamoto Y, et al. Increased frequency of dysfunctional siglec-7− CD57+ PD-1+ natural killer cells in patients with non-alcoholic fatty liver disease. Front Immunol. 2021;12:603133.
Article
CAS
PubMed
PubMed Central
Google Scholar
Sanchez-Correa B, et al. Modulation of NK cells with checkpoint inhibitors in the context of cancer immunotherapy. Cancer Immunol Immunother. 2019;68(5):861–70.
Article
CAS
PubMed
Google Scholar
Zhang Q, et al. Blockade of the checkpoint receptor TIGIT prevents NK cell exhaustion and elicits potent anti-tumor immunity. Nat Immunol. 2018;19(7):723–32.
Article
CAS
PubMed
Google Scholar
Liu S, et al. NK cell-based cancer immunotherapy: from basic biology to clinical development. J Hematol Oncol. 2021;14(1):1–17.
Article
PubMed
PubMed Central
Google Scholar
Tarazona R, et al. Current progress in NK cell biology and NK cell-based cancer immunotherapy. Cancer Immunol Immunother. 2020;69(5):879–99.
Article
PubMed
Google Scholar
Bachanova V, Miller JS. NK cells in therapy of cancer. Crit Rev Oncog. 2014;19(1-2).
Takahashi E, et al. Induction of CD16+ CD56bright NK cells with antitumour cytotoxicity not only from CD16− CD56bright NK cells but also from CD16− CD56dim NK cells. Scand J Immunol. 2007;65(2):126–38.
Article
CAS
PubMed
Google Scholar
Srpan K, et al. Shedding of CD16 disassembles the NK cell immune synapse and boosts serial engagement of target cells. J Cell Biol. 2018;217(9):3267–83.
Article
CAS
PubMed
PubMed Central
Google Scholar
Cheng Y, et al. Trispecific killer engager 161519 enhances natural killer cell function and provides anti-tumor activity against CD19-positive cancers. Cancer Biol Med. 2020;17(4):1026.
Article
CAS
PubMed
PubMed Central
Google Scholar
Reusing SB, et al. CD16xCD33 bispecific killer cell engager (BiKE) as potential immunotherapeutic in pediatric patients with AML and biphenotypic ALL. Cancer Immunol Immunother. 2021;70(12):3701–8.
Article
CAS
PubMed
PubMed Central
Google Scholar
Yang Y, Lundqvist A. Immunomodulatory effects of IL-2 and IL-15; implications for cancer immunotherapy. Cancers. 2020;12(12):3586.
Article
CAS
PubMed
PubMed Central
Google Scholar
Guo J, et al. Tumor-conditional IL-15 pro-cytokine reactivates anti-tumor immunity with limited toxicity. Cell Res. 2021;31(11):1190–8.
Article
CAS
PubMed
PubMed Central
Google Scholar
Au KM, Park SI, Wang AZ. Trispecific natural killer cell nanoengagers for targeted chemoimmunotherapy. Sci Adv. 2020;6(27):eaba8564.
Article
CAS
PubMed
PubMed Central
Google Scholar
Larocca CA, et al. An update on the role of talimogene laherparepvec (T-VEC) in the treatment of melanoma: best practices and future directions. Am J Clin Dermatol. 2020;21(6):821–32.
Article
PubMed
Google Scholar
Ferrucci PF, et al. Talimogene laherparepvec (T-VEC): an intralesional cancer immunotherapy for advanced melanoma. Cancers. 2021;13(6):1383.
Article
CAS
PubMed
PubMed Central
Google Scholar
Wang W, Jiang J, Wu C. CAR-NK for tumor immunotherapy: clinical transformation and future prospects. Cancer Lett. 2020;472:175–80.
Article
CAS
PubMed
Google Scholar
Matosevic S. Viral and nonviral engineering of natural killer cells as emerging adoptive cancer immunotherapies. J Immunol Res. 2018.
Johnson C, et al. Feeder-cell-free and serum-free expansion of natural killer cells using Cloudz microspheres, G-Rex6M, and human platelet lysate. Front Immunol. 2022:13.
Ma R, et al. An oncolytic virus expressing IL15/IL15Rα combined with off-the-shelf EGFR-CAR NK cells targets glioblastoma. Cancer Res. 2021;81(13):3635–48.
Article
CAS
PubMed
PubMed Central
Google Scholar
Zhang Q, et al. Combination therapy with EpCAM-CAR-NK-92 cells and regorafenib against human colorectal cancer models. J Immunol Res. 2018.
Laskowski TJ, Biederstädt A, Rezvani K. Natural killer cells in antitumour adoptive cell immunotherapy. Nat Rev Cancer. 2022;22(10):557–75.
Article
CAS
PubMed
PubMed Central
Google Scholar
Shin MH, et al. NK cell-based immunotherapies in cancer. Immune Network. 2020;20(2).
Gasteiger G, et al. IL-2–dependent adaptive control of NK cell homeostasis. J Exp Med. 2013;210(6):1179–87.
Article
CAS
PubMed
PubMed Central
Google Scholar
Bachanova V, et al. Clearance of acute myeloid leukemia by haploidentical natural killer cells is improved using IL-2 diphtheria toxin fusion protein. Blood. 2014;123(25):3855–63.
Article
CAS
PubMed
PubMed Central
Google Scholar
Xiong J, Wang H, Wang Q. Suppressive myeloid cells shape the tumor immune microenvironment. Adv Biol. 2021;5(3):1900311.
Article
Google Scholar
Grabowski MM, et al. Immune suppression in gliomas. J Neuro-Oncol. 2021;151(1):3–12.
Article
Google Scholar
Gong Y, et al. Rosuvastatin enhances VSV-G lentiviral transduction of NK cells via upregulation of the low-density lipoprotein receptor. Mol Ther Methods Clin Dev. 2020;17:634–46.
Article
CAS
PubMed
PubMed Central
Google Scholar
You F, et al. A novel CD7 chimeric antigen receptor-modified NK-92MI cell line targeting T-cell acute lymphoblastic leukemia. Am J Cancer Res. 2019;9(1):64.
CAS
PubMed
PubMed Central
Google Scholar
Rafei H, Daher M, Rezvani K. Chimeric antigen receptor (CAR) natural killer (NK)-cell therapy: leveraging the power of innate immunity. Br J Haematol. 2021;193(2):216–30.
Article
CAS
PubMed
Google Scholar
Marofi F, et al. CAR-NK cell in cancer immunotherapy; a promising frontier. Cancer Sci. 2021;112(9):3427.
Article
CAS
PubMed
PubMed Central
Google Scholar
Daher M, et al. CAR-NK cells: the next wave of cellular therapy for cancer. Clin Transl Immunol. 2021;10(4):e1274.
Article
CAS
Google Scholar
Siegler EL, et al. Off-the-shelf CAR-NK cells for cancer immunotherapy. Cell Stem Cell. 2018;23(2):160–1.
Article
CAS
PubMed
Google Scholar
Marofi F, et al. Renaissance of armored immune effector cells, CAR-NK cells, brings the higher hope for successful cancer therapy. Stem Cell Res Ther. 2021;12(1):1–21.
Article
Google Scholar
Pan K, et al. CAR race to cancer immunotherapy: from CAR T, CAR NK to CAR macrophage therapy. J Exp Clin Cancer Res. 2022;41(1):1–21.
Article
Google Scholar